For investors with a long-term mindset, the most powerful force in wealth creation is compounding.
Find a high-quality business that can grow earnings consistently, reinvest wisely, and defend its competitive edge — and over time, it can deliver exponential returns.
With that in mind, listed below are three ASX growth shares that may not just reward investors in the short term but could keep compounding value over the next decade and beyond according to analysts. They are as follows:
Image source: Getty Images
Light & Wonder Inc (ASX: LNW)
Light & Wonder has quietly become a major player in the global gaming industry. It operates across three segments: land-based gaming machines, social gaming, and digital iGaming platforms.
The company is benefitting from a growing global appetite for immersive and mobile-friendly casino gaming. Its digital division, in particular, is experiencing strong growth as more jurisdictions open up to online betting and gaming platforms.
With a focus on recurring revenue, strong intellectual property (including some of the industry's best-known slot titles), and improving margins, Light & Wonder is in a strong position to deliver reliable growth.
Bell Potter is very bullish on its long term outlook. It recently put a buy rating and $194.00 price target on its shares.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another ASX growth share that could be a top buy is Telix Pharmaceuticals.
It focuses on radiopharmaceuticals, which are targeted therapies and imaging tools used in cancer diagnostics and treatment.
Telix's flagship product, Illuccix, is already approved and generating strong revenues. In fact, the company recently posted first quarter FY 2025 revenue of US$186 million, up 62% from the prior corresponding period.
With a pipeline that includes multiple potential blockbusters and partnerships expanding its reach globally, Telix is one of the rare biotech stocks already producing revenue while holding enormous upside through R&D.
This is another share that Bell Potter is very bullish on. The broker has a buy rating and $34.00 price target on its shares.
Xero Ltd (ASX: XRO)
Xero has long been one of the ASX's most admired growth shares. The cloud-based accounting platform has grown from a small startup to a global small business software leader with 4.4 million subscribers across Australia, New Zealand, the UK, and North America.
Recent acquisitions and product expansions (including payments and AI integration) have widened Xero's economic moat, enabling deeper engagement with existing customers and higher average revenue per user (ARPU).
And with a total addressable market estimated to be 100 million, it still has bucketloads of growth ahead of it.
Morgan Stanley has an overweight rating and $235.00 price target on its shares.
